159 related articles for article (PubMed ID: 8816892)
1. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
3. Morphologic spectrum of estrogen receptor-negative breast carcinoma.
Scawn R; Shousha S
Arch Pathol Lab Med; 2002 Mar; 126(3):325-30. PubMed ID: 11860308
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
5. c-erb B-2 and p53 expression in breast cancer fine needle aspirates.
Tiniakos DG; Robinson KB; Greenwood H; Cullen P; Cook AI; Horne CH; Angus B
Cytopathology; 1996 Jun; 7(3):178-86. PubMed ID: 8782990
[TBL] [Abstract][Full Text] [Related]
6. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
7. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
9. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
10. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
11. Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study.
Tweedie E; Tonkin K; Kerkvliet N; Doig GS; Sparrow RK; O'Malley FP
Clin Invest Med; 1997 Oct; 20(5):300-7. PubMed ID: 9336655
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cytosolic p53 protein in breast cancer.
Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
[TBL] [Abstract][Full Text] [Related]
14. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.
MacGrogan G; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
Breast Cancer Res Treat; 1995; 36(1):71-81. PubMed ID: 7579509
[TBL] [Abstract][Full Text] [Related]
16. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
17. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
18. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
Kourea HP; Koutras AK; Scopa CD; Marangos MN; Tzoracoeleftherakis E; Koukouras D; Kalofonos HP
Mol Pathol; 2003 Dec; 56(6):328-35. PubMed ID: 14645695
[TBL] [Abstract][Full Text] [Related]
19. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
20. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]